Sean Miller

Investor’s Watch List: Autodesk, Inc. (NASDAQ:ADSK)

Autodesk, Inc. (NASDAQ:ADSK) share price plunged -1.89% or -1.67 points to reach at $86.73 during previous trading session. The stock’s price fluctuated within the range of $85.97 – $89.15 during previous trading session. A total of 8.11M shares exchanged hands, whereas the company’s average trading volume stands at 2.25M shares. Autodesk, Inc. (NASDAQ:ADSK) has a market capitalization of $19.86B and most recently 222.56M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Autodesk, Inc. (NASDAQ:ADSK) is at 55.76.

According to sentiments of 17 analysts the mean estimates of short term price target for the company’s stock is marked at $87.47. The most optimistic analyst sees the stock reaching $105 while the most conventional predicts the target price at $49.

The consensus mean EPS for the current quarter is at $-0.24 derived from a total of 16 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.27 and can go high up to $-0.2. However a year ago during same quarter Autodesk, Inc. (NASDAQ:ADSK) reported $-0.1 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.15 per share according to consensus of 17 analysts.

According to sentiments of 16 analysts the company is expected to report revenues of $470.36M for the current quarter. Bearish revenue estimates established at $460.8M while the bullish revenue forecast has been figured out at $479.2M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.20 on the shares of Autodesk, Inc. (NASDAQ:ADSK). Out of rating recommendations 6 have given the stock a Buy while 6 recommend the stock as Outperform. 6 have given the stock a Hold rating, 2 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Autodesk, Inc. (NASDAQ:ADSK)’s distance from 20 day simple moving average is 0.88% whereas its distance from 50 day simple moving average is 4.28% along with 22.76% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Autodesk, Inc. (NASDAQ:ADSK) shares were trading -2.75% below from the 52-week high mark of $89.18 and +74.09% above from the 52-week bottom of $49.82. The stock hit its 52-week high price on 03/01/17 and 52-week low price on 06/27/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 2.96% in the past one week and soared 2.59% during previous one month drive, the stock went up 8.86% during past quarter. In the last six months the stock’s performance soared 32.39% while yearly performance of the company advanced 52.24%. The company’s year to date (YTD) performance is at 17.19%.

While taking a glance at financials, we can look at a number of key indicators. Autodesk, Inc. (NASDAQ:ADSK) has a Return on Assets (ROA) of -11.70%. The company currently has a Return on Equity (ROE) of -50.80% and a Return on Investment (ROI) of -24.90%. Average true range (ATR-14) of the company sets at 2.11, along with its weekly and monthly volatility of 2.48%, 2.24% respectively. Beta value of the stock stands at 2.05.

The company’s price to free cash flow for trailing twelve months is 201.51. Its quick ratio for most recent quarter is 1.10 along with current ratio for most recent quarter of 1.10. Total debt to equity ratio of the company for most recent quarter is 2.02 whereas long term debt to equity ratio for most recent quarter is 1.48.

Experts Analysis on Share Rating and Recommendation: Occidental Petroleum Corporation (NYSE:OXY)

Occidental Petroleum Corporation (NYSE:OXY) rose 3.20% during previous trade. BofA/Merrill issued rating on the stock of Occidental Petroleum Corporation (NYSE:OXY) in a research note issued to investors on Mar-15-17, the stock received “Upgrade” rating from Neutral to Buy. Additionally Credit Suisse issued their verdict on the stock of the company, on record date of Mar-14-17 the stock was “Upgraded” from Neutral to Outperform besides that on Feb-13-17 Occidental Petroleum Corporation (NYSE:OXY) was “Downgraded” by Mizuho from Buy to Neutral from $87 to $70. Furthermore on Jan-04-17 the stock was “Downgraded” by BofA/Merrill from Buy to Neutral.

Occidental Petroleum Corporation (NYSE:OXY) shares ended last trading session at the price of $65.06 whereas a number of traders indicating mean target price will hit $75.09 over the next twelve months, mean value of price target most recently revised on 03/14/17. Occidental Petroleum Corporation (NYSE:OXY)’s highest estimates of price target are $91 and low forecast is $62 based on the opinion of 23 analysts. The price target estimates represents a standard deviation of 7.08. However brokerage recommendations suggests an ABR of 2.81 based on calls of 16 experts, where 3 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 10 suggest Hold, 0 are rating the stock as Sell while 2 as Strong Sell.

Occidental Petroleum Corporation (NYSE:OXY) is expected to release the earnings of its current quarter on 5/4/17. The company is expected to release $0.17 EPS for current quarter according to 18 analysts whereas the company reported $-0.56 EPS during same quarter a year ago. For the current quarter the stock has lowest EPS estimates of $-0.15 and high estimate of $0.49. For the current year Occidental Petroleum Corporation (NYSE:OXY) has set to release EPS of $1.13 as per the sentiments of 24 analysts, however according to 22 analysts, the company expected to release $1.99 EPS for next year.

Occidental Petroleum Corporation (NYSE:OXY)’s average revenue estimates for the current quarter are $2.96B according to 6 number of analysts. However its lowest revenue estimates are $2.52B and highest revenue estimates are $3.29B. A year ago the company’s sales were $2.28B. Its yearly sales growth estimates are 29.80%. For the next quarter the company has anticipated average revenues of $3.29B, according to the sentiments of 6 analysts. For the current year the company has fixed $13.58B revenues, as per the opinion of 10 analysts. For the current year the company has low revenue estimates of $12B in contradiction of high revenue estimates of $16.38B. Whereas for the next year revenues are set at $14.8B by 9 analysts.

The stock exchanged hands 7.29M shares versus average trading capacity of 5.62M shares, while its shares’ total market worth is $49.85B along with 764.29M outstanding shares. Occidental Petroleum Corporation (NYSE:OXY) shares were trading -14.57% below from the 52-week high price mark of $76.15 and +6.64% above from the 52-week price bottom of $61.01. However the company observed 52 week high price on 08/30/16 and witnessed 52 week low price on 03/09/17. The company’s price sits -2.40% below from its 50-day moving average of $66.22 and -7.38% away from the stock’s 200-day moving average which is $70.12. Occidental Petroleum Corporation (NYSE:OXY)’s price to sales ratio for trailing twelve month stands at 4.87, whereas its price to book ratio for most recent quarter sits at 2.31. However the company’s price to cash per share for most recent quarter stands at 22.23.

Watch List: Kinross Gold Corporation (USA) (NYSE:KGC)

Kinross Gold Corporation (USA) (NYSE:KGC) share price soared 8.78% or 0.28 points to reach at $3.47 during previous trading session. The stock’s price fluctuated within the range of $3.15 – $3.49 during previous trading session. A total of 19.16M shares exchanged hands, whereas the company’s average trading volume stands at 12.06M shares. Kinross Gold Corporation (USA) (NYSE:KGC) has a market capitalization of $4.23B and most recently 1.25B outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Kinross Gold Corporation (USA) (NYSE:KGC) is at 49.50.

According to sentiments of 20 analysts the mean estimates of short term price target for the company’s stock is marked at $4.40. The most optimistic analyst sees the stock reaching $6 while the most conventional predicts the target price at $2.59.

The consensus mean EPS for the current quarter is at $0.01 derived from a total of 8 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.02 and can go high up to $0.03.

According to sentiments of 4 analysts the company is expected to report revenues of $800.29M for the current quarter. Bearish revenue estimates established at $769.86M while the bullish revenue forecast has been figured out at $848.48M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.91 on the shares of Kinross Gold Corporation (USA) (NYSE:KGC). Out of rating recommendations 1 have given the stock a Buy while 4 recommend the stock as Outperform. 15 have given the stock a Hold rating, 0 as Underperform and 2 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Kinross Gold Corporation (USA) (NYSE:KGC)’s distance from 20 day simple moving average is -2.03% whereas its distance from 50 day simple moving average is -4.01% along with -15.90% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Kinross Gold Corporation (USA) (NYSE:KGC) shares were trading -40.38% below from the 52-week high mark of $5.82 and +24.37% above from the 52-week bottom of $2.79. The stock hit its 52-week high price on 5/2/16 and 52-week low price on 12/22/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 6.77% in the past one week and plunged -12.81% during previous one month drive, the stock went up 4.83% during past quarter. In the last six months the stock’s performance fell -13.68% while yearly performance of the company advanced 17.63%.The company’s year to date (YTD) performance is at 11.58%.

While taking a glance at financials, we can look at a number of key indicators. Kinross Gold Corporation (USA) (NYSE:KGC) has a Return on Assets (ROA) of -1.30%. The company currently has a Return on Equity (ROE) of -2.50% and a Return on Investment (ROI) of -0.10%. Average true range (ATR-14) of the company sets at 0.37, along with its weekly and monthly volatility of 5.12%, 4.70% respectively. Beta value of the stock stands at 0.37.

The company’s price to free cash flow for trailing twelve months is 9.28. Its quick ratio for most recent quarter is 1.70 along with current ratio for most recent quarter of 3.30. Total debt to equity ratio of the company for most recent quarter is 0.42 whereas long term debt to equity ratio for most recent quarter is 0.42.

Momentum Stock: Cerulean Pharma Inc (NASDAQ:CERU)

Cerulean Pharma Inc (NASDAQ:CERU) share price soared 33.04% or 0.74 points to reach at $2.98 during previous trading session. The stock’s price fluctuated within the range of $2.33 – $3.47 during previous trading session. A total of 31.56M shares exchanged hands, whereas the company’s average trading volume stands at 3.80M shares. Cerulean Pharma Inc (NASDAQ:CERU) has a market capitalization of $73.55M and most recently 27.44M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Cerulean Pharma Inc (NASDAQ:CERU) is at 82.50.

According to sentiments of 2 analysts the mean estimates of short term price target for the company’s stock is marked at $3.75. The most optimistic analyst sees the stock reaching $6 while the most conventional predicts the target price at $1.50.

The consensus mean EPS for the current quarter is at $-0.34 derived from a total of 2 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.37 and can go high up to $-0.3. However a year ago during same quarter Cerulean Pharma Inc (NASDAQ:CERU) reported $-0.39 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.31 per share according to consensus of 1 analyst.

According to sentiments of 1 analyst the company is expected to report revenues of $5M for the current quarter. Bearish revenue estimates established at $5M while the bullish revenue forecast has been figured out at $5M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.33 on the shares of Cerulean Pharma Inc (NASDAQ:CERU). Out of rating recommendations 1 have given the stock a Buy while 0 recommend the stock as Outperform. 2 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Cerulean Pharma Inc (NASDAQ:CERU)’s distance from 20 day simple moving average is 103.76% whereas its distance from 50 day simple moving average is 162.04% along with 113.53% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Cerulean Pharma Inc (NASDAQ:CERU) shares were trading -31.18% below from the 52-week high mark of $4.33 and +372.78% above from the 52-week bottom of $0.63. The stock hit its 52-week high price on 04/21/16 and 52-week low price on 11/08/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 114.39% in the past one week and soared 93.51% during previous one month drive, the stock went up 292.36% during past quarter. In the last six months the stock’s performance advanced 192.16% while yearly performance of the company advanced 38.60%. The company’s year to date (YTD) performance is at 320.79%.

While taking a glance at financials, we can look at a number of key indicators. Cerulean Pharma Inc (NASDAQ:CERU) has a Return on Assets (ROA) of -77.90%. The company currently has a Return on Equity (ROE) of -141.70%. Average true range (ATR-14) of the company sets at 0.30, along with its weekly and monthly volatility of 24.96%, 12.17% respectively.

The company’s quick ratio for most recent quarter is 2.50 along with current ratio for most recent quarter of 2.50. Total debt to equity ratio of the company for most recent quarter is 0.89 whereas long term debt to equity ratio for most recent quarter is 0.40.

Stock on the Move: CytRx Corporation (NASDAQ:CYTR)

Shares of CytRx Corporation (NASDAQ:CYTR) jumped 1.91% to reach at $0.42 during previous trading session. The company has experienced volume of 1,742,675 shares while on average the company has a capacity of trading 1.28M share.

CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical research and development company specializing in oncology, on March 15, 2017 announced financial results for the year ended December 31, 2016, and provided an overview of recent accomplishments and upcoming milestones for its research and development programs.

Fourth Quarter 2016 and Recent Highlights:

Granted Type B Pre-NDA Meeting with FDA for Aldoxorubicin.  In January 2017, CytRx announced that, in response to a request from the Company, the FDA has agreed to a Type B pre-NDA meeting at which the Company will seek input on its plans for a NDA for aldoxorubicin as a treatment for patients with STS.

Strengthened the Balance Sheet with $8.1 Million in Financing. In December 2016, CytRx announced its entry into securities purchase agreements with existing institutional investors to purchase shares of its common and preferred stock at a purchase price of $0.42 per share in a registered direct offering with gross proceeds of $8.1 million.

CytRx Corporation (NASDAQ:CYTR) holds the market capitalization of $49.92M along with 111.32M outstanding shares. During the last trade, stock’s minimum price has been reached out at $0.41 while the maximum trading price moved at $0.43. Currently the stock price is moving -89.07% off from the highest level of twelve months and +11.11% above from twelve months low. CytRx Corporation (NASDAQ:CYTR) marked 52-week highest price level of $3.66 on 04/25/16 and 52-week lowest price level of $0.36 on 12/28/16. For the stock, price target value has been calculated at $2.38 based on calls of 2 experts. Stock’s minimum price target estimates has been figured out at $0.75 while the maximum price target forecast is established at $4.00.

As of current trade, CytRx Corporation (NASDAQ:CYTR)’s six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -79.31%. Year-to-date (YTD) performance of the stock illustrate upbeat trend of 13.51%. Shares of CytRx Corporation (NASDAQ:CYTR) currently have an ABR of 2.00, derived from a total of 2 opinions. The company’s price sits -5.44% below from its 50-day moving average of $0.42 and -49.14% below from the stock’s 200-day moving average of $0.48. The company has Relative Strength Index (RSI 14) of 38.96 along with Average True Range (ATR 14) of 0.02. Its weekly and monthly volatility is 4.89%, 5.80% respectively. The company’s beta value is at 1.21.

CytRx Corporation (NASDAQ:CYTR)’s price to sales ratio for trailing twelve months is 239.36 and price to book ratio for most recent quarter is 1.62, whereas price to cash per share for the most recent quarter is 0.81. CytRx Corporation (NASDAQ:CYTR)’s quick ratio for most recent quarter is 3.10 along with current ratio for most recent quarter of 3.10. Total debt to equity ratio of the company for most recent quarter is 1.01 whereas long term debt to equity ratio for most recent quarter is 0.86. CytRx Corporation (NASDAQ:CYTR) has a Return on Assets of -98.10%. The company currently has a Return on Equity of -209.90% and Return on Investment of -143.50%.

Stock Earnings Alert: Concordia International Corp (NASDAQ:CXRX)

Shares of Concordia International Corp (NASDAQ:CXRX) fell -9.59% to reach at $1.98 during previous trading session. The company has experienced volume of 1,830,818 shares while on average the company has a capacity of trading 1.21M share.

Concordia International Corp (NASDAQ:CXRX) an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, on March 15, 2017 announced its financial and operational results for the three and twelve months ended December 31, 2016.

Fourth Quarter 2016 Financial Results:

Consolidated revenue of $170.4 million, a decrease of 8.1% compared with the third quarter of 2016.

GAAP net loss includes fourth quarter impairment charges of $562.1 million, and GAAP loss per share of $13.00. The impairment charges consisted of $306.9 million related to the Company’s North America segment product portfolio and $255.2 million related to the Company’s International segment product portfolio.

Adjusted EBITDA of $80.5 million and adjusted earnings per share of $0.13, includes a charge of $4.5 million of previously capitalized research and development expenses related to the Company’s phase 3 trial for Photodynamic Therapy with Photofrin.

Reported Concordia International segment results in the fourth quarter that were 1.3% higher on a constant currency basis compared to the third quarter of 2016, increasing from £104.6 million to £106.0 million in the period.

Concordia International Corp (NASDAQ:CXRX) holds the market capitalization of $101.01M. During the last trade, stock’s minimum price has been reached out at $1.81 while the maximum trading price moved at $2.03. Currently the stock price is moving -94.24% off from the highest level of twelve months and +17.16% above from twelve months low. Concordia International Corp (NASDAQ:CXRX) marked 52-week highest price level of $34.40 on 06/02/16 and 52-week lowest price level of $1.69 on 11/08/16. For the stock, price target value has been calculated at $8.04 based on calls of 7 experts. Stock’s minimum price target estimates has been figured out at $1.00 while the maximum price target forecast is established at $45.00.

As of current trade, Concordia International Corp (NASDAQ:CXRX) has shown weekly downbeat performance of -5.26%. Its six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -93.53%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -6.60%. Shares of Concordia International Corp (NASDAQ:CXRX) currently have an ABR of 3.17, derived from a total of 6 opinions. The company’s price sits -12.76% below from its 50-day moving average of $2.34 and -76.11% below from the stock’s 200-day moving average of $3.40. The company has Relative Strength Index (RSI 14) of 40.58 along with Average True Range (ATR 14) of 0.25. Its weekly and monthly volatility is 7.14%, 8.01% respectively.

Concordia International Corp (NASDAQ:CXRX)’s price to sales ratio for trailing twelve months is 0.12 and price to book ratio for most recent quarter is 0.34.

Notable Mover: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) share price soared 12.68% or 0.18 points to reach at $1.60 during previous trading session. The stock’s price fluctuated within the range of $1.55 – $1.70 during previous trading session. A total of 14.81M shares exchanged hands, whereas the company’s average trading volume stands at 1.26M shares. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $383.90M and most recently 245.47M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is at 60.14.

According to sentiments of 2 analysts the mean estimates of short term price target for the company’s stock is marked at $5. The most optimistic analyst sees the stock reaching $6 while the most conventional predicts the target price at $4.

The consensus mean EPS for the current quarter is at $-0.08 derived from a total of 3 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.1 and can go high up to $-0.06. However a year ago during same quarter Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported $-0.09 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.08 per share according to consensus of 3analysts.

According to sentiments of 2 analysts the company is expected to report revenues of $8.75M for the current quarter. Bearish revenue estimates established at $8.5M while the bullish revenue forecast has been figured out at $9M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.43 on the shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Out of rating recommendations 1 have given the stock a Buy while 2 recommend the stock as Outperform. 4 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s distance from 20 day simple moving average is 7.49% whereas its distance from 50 day simple moving average is 8.20% along with -0.42% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares were trading -25.93% below from the 52-week high mark of $2.16 and +19.24% above from the 52-week bottom of $1.34. The stock hit its 52-week high price on 06/09/16 and 52-week low price on 01/20/17.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 11.11% in the past one week and soared 9.59% during previous one month drive, the stock went up 14.29% during past quarter. In the last six months the stock’s performance advanced 6.67% while yearly performance of the company advanced 11.11%. The company’s year to date (YTD) performance is at 12.68%.

While taking a glance at financials, we can look at a number of key indicators. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a Return on Assets (ROA) of -39.50%. The company currently has a Return on Equity (ROE) of -339.10% and a Return on Investment (ROI) of -84.70%. Average true range (ATR-14) of the company sets at 0.08, along with its weekly and monthly volatility of 4.74%, 4.79% respectively. Beta value of the stock stands at -0.96.

The company’s quick ratio for most recent quarter is 2.10 along with current ratio for most recent quarter of 2.20. Total debt to equity ratio of the company for most recent quarter is 20.03 whereas long term debt to equity ratio for most recent quarter is 19.

Analyst Views and Recommendations: Intel Corporation (NASDAQ:INTC)

Intel Corporation (NASDAQ:INTC) fell -0.23% during previous trade. Credit Suisse issued rating on the stock of Intel Corporation (NASDAQ:INTC) in a research note issued to investors on Mar-15-17, the stock received “Downgrade” rating from Outperform to Neutral. Additionally Bernstein issued their verdict on the stock of the company, on record date of Mar-01-17 the stock was “Downgraded” from Mkt Perform to Underperform besides that on Feb-10-17 Intel Corporation (NASDAQ:INTC) was “Downgraded” by Canaccord Genuity from Buy to Hold from $43 to $38. Furthermore on Jan-27-17 the stock was “Upgraded” by Morgan Stanley from Underweight to Equal-Weight.

Intel Corporation (NASDAQ:INTC) shares ended last trading session at the price of $35.10 whereas a number of traders indicating mean target price will hit $40.34 over the next twelve months, mean value of price target most recently revised on 03/14/17. Intel Corporation (NASDAQ:INTC)’s highest estimates of price target are $45 and low forecast is $30 based on the opinion of 32 analysts. The price target estimates represents a standard deviation of 3.46. However brokerage recommendations suggests an ABR of 1.96 based on calls of 28 experts, where 16 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 9 suggest Hold, 0 are rating the stock as Sell while 2 as Strong Sell.

Intel Corporation (NASDAQ:INTC) is expected to release the earnings of its current quarter on 4/18/17. The company is expected to release $0.65 EPS for current quarter according to 30 analysts whereas the company reported $0.54 EPS during same quarter a year ago. For the current quarter the stock has lowest EPS estimates of $0.64 and high estimate of $0.65. For the current year Intel Corporation (NASDAQ:INTC) has set to release EPS of $2.8 as per the sentiments of 36 analysts, however according to 36 analysts, the company expected to release $2.93 EPS for next year.

Intel Corporation (NASDAQ:INTC)’s average revenue estimates for the current quarter are $14.81B according to 32 number of analysts. However its lowest revenue estimates are $14.77B and highest revenue estimates are $14.94B. A year ago the company’s sales were $13.8B. Its yearly sales growth estimates are 7.30%. For the next quarter the company has anticipated average revenues of $14.37B, according to the sentiments of 32 analysts. For the current year the company has fixed $60.01B revenues, as per the opinion of 39 analysts. For the current year the company has low revenue estimates of $59.25B in contradiction of high revenue estimates of $64.08B. Whereas for the next year revenues are set at $61.47B by 37 analysts.

The stock exchanged hands 27.96M shares versus average trading capacity of 25.99M shares, while its shares’ total market worth is $166.43B along with 4.73B outstanding shares. Intel Corporation (NASDAQ:INTC) shares were trading -8.06% below from the 52-week high price mark of $38.18 and +21.65% above from the 52-week price bottom of $28.85. However the company observed 52 week high price on 01/27/17 and witnessed 52 week low price on 05/19/16. The company’s price sits -3.24% below from its 50-day moving average of $36.22 and 0.47% far from the stock’s 200-day moving average which is $36.15. Intel Corporation (NASDAQ:INTC)’s price to sales ratio for trailing twelve month stands at 2.79, whereas its price to book ratio for most recent quarter sits at 2.51. However the company’s price to cash per share for most recent quarter stands at 9.70.

Experts Analysis: Harmonic Inc (NASDAQ:HLIT)

Harmonic Inc (NASDAQ:HLIT) fell -3.42% during previous trade. Drexel Hamilton issued rating on the stock of Harmonic Inc (NASDAQ:HLIT) in a research note issued to investors on Mar-14-17, the stock received “Downgrade” rating from Buy to Hold. Additionally Dougherty & Company issued their verdict on the stock of the company, on record date of Dec-06-16 the stock was “Initiated” as Buy at $7 besides that on Aug-10-16 Harmonic Inc (NASDAQ:HLIT) was “Upgraded” by Drexel Hamilton from Hold to Buy. Furthermore on Jul-23-15 the stock was “Initiated” by Drexel Hamilton as Hold.

Harmonic Inc (NASDAQ:HLIT) shares ended last trading session at the price of $5.65 whereas a number of traders indicating mean target price will hit $6.35 over the next twelve months, mean value of price target most recently revised on 03/01/17. Harmonic Inc (NASDAQ:HLIT)’s highest estimates of price target are $7 and low forecast is $4.75 based on the opinion of 5 analysts. The price target estimates represents a standard deviation of 1.07. However brokerage recommendations suggests an ABR of 2.40 based on calls of 5 experts, where 2 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 1 suggest Hold, 0 are rating the stock as Sell while 1 as Strong Sell.

Harmonic Inc (NASDAQ:HLIT) is expected to release the earnings of its current quarter on 5/9/17. The company is expected to release $-0.05 EPS for current quarter according to 5 analysts whereas the company reported $-0.11 EPS during same quarter a year ago. For the current quarter the stock has lowest EPS estimates of $-0.06 and high estimate of $-0.04. For the current year Harmonic Inc (NASDAQ:HLIT) has set to release EPS of $0.21 as per the sentiments of 5 analysts, however according to 4 analysts, the company expected to release $0.35 EPS for next year.

Harmonic Inc (NASDAQ:HLIT)’s average revenue estimates for the current quarter are $92.62M according to 6 number of analysts. However its lowest revenue estimates are $90M and highest revenue estimates are $94.7M. A year ago the company’s sales were $82.45M. Its yearly sales growth estimates are 12.30%. For the next quarter the company has anticipated average revenues of $104.8M, according to the sentiments of 6 analysts. For the current year the company has fixed $438.99M revenues, as per the opinion of 6 analysts. For the current year the company has low revenue estimates of $430.2M in contradiction of high revenue estimates of $445M. Whereas for the next year revenues are set at $495.23M by 5 analysts.

The stock exchanged hands 1.15M shares versus average trading capacity of 657,803 shares, while its shares’ total market worth is $450.72M along with 79.77M outstanding shares. Harmonic Inc (NASDAQ:HLIT) shares were trading -8.58% below from the 52-week high price mark of $6.18 and +125.10% above from the 52-week price bottom of $2.51. However the company observed 52 week high price on 03/08/17 and witnessed 52 week low price on 05/19/16. The company’s price sits 5.06% above from its 50-day moving average of $5.49 and 24.25% far from the stock’s 200-day moving average which is $5.17. Harmonic Inc (NASDAQ:HLIT)’s price to sales ratio for trailing twelve month stands at 1.12, whereas its price to book ratio for most recent quarter sits at 1.64. However the company’s price to cash per share for most recent quarter stands at 7.27.

Analyst Recommendations Roundup: Mobileye NV (NYSE:MBLY)

Mobileye NV (NYSE:MBLY) rose 0.56% during previous trade. Wells Fargo issued rating on the stock of Mobileye NV (NYSE:MBLY) in a research note issued to investors on Mar-14-17, the stock received “Downgrade” rating from Outperform to Market Perform. Additionally SunTrust issued their verdict on the stock of the company, on record date of Mar-14-17the stock was “Downgraded” from Buy to Hold besides that on Mar-14-17Mobileye NV (NYSE:MBLY) was “Downgraded” by RBC Capital Mkts from Outperform to Sector Perform from $57 to $63.54. Furthermore on Mar-14-17the stock was “Downgraded” by Raymond James from Outperform to Mkt Perform.

Mobileye NV (NYSE:MBLY) shares ended last trading session at the price of $60.96 whereas a number of traders indicating mean target price will hit $59.21 over the next twelve months, mean value of price target most recently revised on 03/13/17. Mobileye NV (NYSE:MBLY)’s highest estimates of price target are $66 and low forecast is $40 based on the opinion of 20 analysts. The price target estimates represents a standard deviation of 8.79. However brokerage recommendations suggests an ABR of 2.16 based on calls of 19 experts, where 7 brokers polls the stock a Strong Buy, 4 suggest the stock a Buy, 7 suggest Hold, 0 are rating the stock as Sell while 1 as Strong Sell.

Mobileye NV (NYSE:MBLY) is expected to release the earnings of its current quarter on 5/4/17. The company is expected to release $0.24 EPS for current quarter according to 19 analysts whereas the company reported $0.15 EPS during same quarter a year ago. For the current quarter the stock has lowest EPS estimates of $0.21 and high estimate of $0.27. For the current year Mobileye NV (NYSE:MBLY) has set to release EPS of $1.02 as per the sentiments of 22 analysts, however according to 21 analysts, the company expected to release $1.54 EPS for next year.

Mobileye NV (NYSE:MBLY)’s average revenue estimates for the current quarter are $117.86M according to 18 number of analysts. However its lowest revenue estimates are $103.63M and highest revenue estimates are $124.4M. A year ago the company’s sales were $75.21M. Its yearly sales growth estimates are 56.70%. For the next quarter the company has anticipated average revenues of $122.32M, according to the sentiments of 18 analysts. For the current year the company has fixed $499.69M revenues, as per the opinion of 23 analysts. For the current year the company has low revenue estimates of $493.17M in contradiction of high revenue estimates of $511M. Whereas for the next year revenues are set at $730.38M by 22 analysts.

The stock exchanged hands 26.43M shares versus average trading capacity of 6.35M shares, while its shares’ total market worth is $17.33B along with 221.74M outstanding shares. Mobileye NV (NYSE:MBLY) shares were trading -0.89% below from the 52-week high price mark of $61.51 and +84.22% above from the 52-week price bottom of $33.09. However the company observed 52 week high price on 03/13/17 and witnessed 52 week low price on 03/16/16. The company’s price sits 38.12% above from its 50-day moving average of $44.95 and 44.56% far from the stock’s 200-day moving average which is $41.25. Mobileye NV (NYSE:MBLY)’s price to sales ratio for trailing twelve month stands at 37.43, whereas its price to book ratio for most recent quarter sits at 19.41. However the company’s price to cash per share for most recent quarter stands at 33.56. Its price to free cash flow for trailing twelve months is 89.02.